In vitro activity of Tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian
Jin Yang Baek1, Cheol-In Kang2, So Hyun Kim3
1Asia Pacific Foundation for Infection Diseases (APFID), Seoul, Republic of Korea.
Abstract:
Tedizolid phosphate is a second-generation oxazolidinone prodrug that is potential activity against a wide range of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, penicillin-resistant streptococci, and vancomycin-resistant enterococci. The in vitro activity of tedizolid and other comparator agents against multidrug-resistant (MDR) pneumococci from various Asian countries were evaluated. Of the S. pneumoniae clinical pneumonia isolates collected during 2008 and 2009 from 8 Asian countries (Korea, Taiwan, Thailand, Hong Kong, Vietnam, Malaysia, Philippines, and Sri Lanka), 104 isolates of MDR pneumococci were included in this study. Antimicrobial susceptibility testing for 18 antimicrobial agents was performed by broth microdilution method. Tedizolid was highly active against pneumococci. All isolates tested were inhibited at a tedizolid minimum inhibitory concentration (MIC) value of ≤0.25μg/ml (ranged from ≤0.03μg/ml to 0.25μg/ml). The MIC50 and MIC90 of tedizolid against MDR pneumococci were both 0.12μg/ml, while MIC50 and MIC90 of linezolid were 0.5μg/ml and 1μg/ml, respectively. In addition, tedizolid maintained the activity against S. pneumoniae regardless of the extensively drug-resistant (XDR) phenotype of the isolates. The activity of tedizolid was excellent against all types of MDR pneumococci, exhibiting and maintaining at least 4-fold-greater potency compared to linezolid, regardless of resistance phenotypes to other commonly utilized agents. Tedizolid has the potential to be an agent to treat infections caused by MDR pneumococci in the Asia.
Insights
Tedizolid phosphate shows excellent in vitro activity against multidrug-resistant pneumococci from Asia. This oxazolidinone is more potent than linezolid, offering a promising option for treating resistant bacterial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Gram-positive pathogens, including drug-resistant strains, pose a significant threat.
- Oxazolidinones are a crucial class of antibiotics for treating resistant Gram-positive infections.
- Multidrug-resistant (MDR) Streptococcus pneumoniae is a growing concern, particularly in Asia.
Purpose of the Study:
- To evaluate the in vitro activity of tedizolid phosphate against MDR pneumococci collected from Asian countries.
- To compare the efficacy of tedizolid with other antimicrobial agents, including linezolid.
- To assess tedizolid's activity against extensively drug-resistant (XDR) Streptococcus pneumoniae isolates.
Main Methods:
- Collected 104 MDR Streptococcus pneumoniae isolates from 8 Asian countries between 2008-2009.
- Performed antimicrobial susceptibility testing using the broth microdilution method for 18 agents.
- Determined minimum inhibitory concentrations (MICs) for tedizolid and comparator drugs.
Main Results:
- Tedizolid demonstrated high in vitro activity against all MDR pneumococci tested, with MIC values ≤0.25 μg/mL.
- MIC50 and MIC90 values for tedizolid were 0.12 μg/mL, significantly lower than linezolid (0.5 μg/mL and 1 μg/mL, respectively).
- Tedizolid maintained potent activity against extensively drug-resistant (XDR) Streptococcus pneumoniae isolates, showing at least 4-fold greater potency than linezolid.
Conclusions:
- Tedizolid exhibits excellent in vitro activity against a wide range of MDR and XDR pneumococci prevalent in Asia.
- Tedizolid demonstrates superior potency compared to linezolid against these resistant pathogens.
- Tedizolid phosphate represents a potential therapeutic agent for infections caused by MDR pneumococci in the Asian region.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA